Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients

International Journal of Cancer

Volumn 142, Issue 5, 2018, Pages 940-948

  Hosry, Jeff ^a   Miranda, Roberto N ^a   Samaniego, Felipe ^a   Economides, Minas P ^a   Torres, Harrys A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

clinicopathologic characteristics; hepatitis C virus; relapse; transformed diffuse large b cell lymphoma

Indexed keywords

ANTIVIRUS AGENT;

AGED; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; FOLLOW UP; HEPACIVIRUS; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85032995789     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.31110     Document Type: Article

References (46)

1. Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin 2017;67:411–31.
2. Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016;4:e609–e616.
3. Tapan U, May SK, Fiore J, et al. Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma. Leuk Lymphoma 2011;52:916–18.
4. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451–8.
5. Peveling-Oberhag J, Arcaini L, Hansmann ML, et al. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169–77.
6. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case–control study. Blood 2003;102:996–9.
7. Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996;87:4296–301.
8. Iqbal T, Mahale P, Turturro F, et al. Prevalence and association of hepatitis C virus infection with different types of lymphoma. Int J Cancer 2016;138:1035–7.
9. Hartridge-Lambert SK, Stein EM, Markowitz AJ, et al. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012;55:634–41.
10. Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001;98:3745–9.
11. Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016;128:2527–32.
12. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89–94.
13. Sultanik P, Klotz C, Brault P, et al. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 2015;125:2446–7.
14. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines. Non-Hodgkin's Lymphomas). Version 3. 2017. http://www.nccn.org. Accessed on June 5, 2017.
15. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol 2011;29:1827–34.
16. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587–94.
17. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202–15.
18. Lin P, Mansoor A, Bueso-Ramos C, et al. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 2003;120:246–53.
19. Yoshino T, Omonishi K, Kobayashi K, et al. Clinicopathological features of gastric mucosa associated lymphoid tissue (MALT) lymphomas: high grade transformation and comparison with diffuse large B cell lymphomas without MALT lymphoma features. J Clin Pathol 2000;53:187–90.
20. Agbay RL, Loghavi S, Medeiros LJ, et al. High-grade transformation of low-grade B-cell lymphoma: pathology and molecular pathogenesis. Am J Surg Pathol 2016;40:e1–e16.
21. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006;24:953–60.
22. Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006;17:1434–40.
23. Hosry J, Mahale P, Turturro F, et al. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer 2016;139:2519–28.
24. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
25. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
26. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–33.
27. Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012;2012:980942.
28. Tasaki K, Shichishima A, Furuta M, et al. CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma. Pathol Int 2007;57:101–7.
29. Wenzel C, Dieckmann K, Fiebiger W, et al. CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leuk Lymphoma 2001;42:823–9.
30. Ferry JA, Yang WI, Zukerberg LR, et al. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 1996;105:31–7.
31. Baseggio L, Traverse-Glehen A, Petinataud F, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 2010;95:604–12.
32. Hardy RR, Hayakawa K, Shimizu M, et al. Rheumatoid factor secretion from human Leu-1+ B cells. Science 1987;236:81–3.
33. Plater-Zyberk C, Maini RN. Phenotypic and functional features of CD5+ B lymphocytes in rheumatoid arthritis. Scand J Rheumatol Suppl 1988;75:76–83.
34. Dauphinee M, Tovar Z, Talal N. B cells expressing CD5 are increased in Sjogren's syndrome. Arthritis Rheum 1988;31:642–7.
35. Pietrogrande M, Corona M, Milani S, et al. Relationship between rheumatoid factor and the immune response against hepatitis C virus in essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13 (Suppl 13):S109–S113.
36. Jain P, Fayad LE, Rosenwald A, et al. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol 2013;88:798–802.
37. Chuang WY, Chang H, Shih LY, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch 2015;467:571–82.
38. Mizuochi T, Ito M, Takai K, et al. Differential susceptibility of peripheral blood CD5+ and CD5– B cells to apoptosis in chronic hepatitis C patients. Biochem Biophys Res Commun 2009;389:512–15.
39. Sarhan MA, Pham TN, Chen AY, et al. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol 2012;86:3723–35.
40. Curry MP, Golden-Mason L, Nolan N, et al. Expansion of peripheral blood CD5+ B cells is associated with mild disease in chronic hepatitis C virus infection. J Hepatol 2000;32:121–5.
41. Zuckerman E. Expansion of CD5+ B-cell overexpressing CD81 in HCV infection: towards better understanding the link between HCV infection, B-cell activation and lymphoproliferation. J Hepatol 2003;38:674–6.
42. Curry MP, Golden-Mason L, Doherty DG, et al. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J Hepatol 2003;38:642–50.
43. Torres HA, Economides MP, Kyvernitakis A, et al. Sofosbuvir-based therapy in patients with chronic Hepatitis c virus infection and malignancies—a prospective observational study of 143 patients. In The 53rd Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, IL, June 2017.
44. Torres HA, McDonald GB. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood 2016;128:1449–57.
45. Qi Z, Wang H, Gao G. Association of risk of non-Hodgkin's lymphoma with hepatitis B virus infection: a meta-analysis. Int J Clin Exp Med 2015;8:22167–74.
46. Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 2016;22:717–22.